Diamyd Medical Valuation Multiples

Diamyd Medical Overview

About Diamyd Medical

Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.

Founded

1994

HQ

Employees

39

Website

diamyd.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($19M)

EV

$10M

Valuation Multiples

Multiples.vc

Start free trial

Diamyd Medical Financials

Diamyd Medical reported last 12-month revenue of — and negative EBITDA of ($19M).

In the same LTM period, Diamyd Medical generated — in gross profit, ($19M) in EBITDA losses, and had net loss of ($18M).

Diamyd Medical P&L

In the most recent fiscal year, Diamyd Medical reported revenue of $14K and EBITDA of ($18M).

Diamyd Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Diamyd Medical Stock Performance

Diamyd Medical has current market cap of $21M, and enterprise value of $10M.

Diamyd Medical's stock price is $0.15.

Diamyd Medical Valuation Multiples

Diamyd Medical trades at 687.9x EV/Revenue multiple, and (0.5x) EV/EBITDA.

Diamyd Medical Financial Valuation Multiples

As of April 18, 2026, Diamyd Medical has market cap of $21M and EV of $10M.

Equity research analysts estimate Diamyd Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Diamyd Medical has a P/E ratio of (1.2x).

Diamyd Medical Margins & Growth Rates

Diamyd Medical's revenue in the last fiscal year grew by 0%.

Diamyd Medical's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

Diamyd Medical Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Diamyd Medical M&A Activity

Diamyd Medical acquired XXX companies to date.

Last acquisition by Diamyd Medical was on XXXXXXXX, XXXXX. Diamyd Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Diamyd Medical Investment Activity

Diamyd Medical invested in XXX companies to date.

Diamyd Medical made its latest investment on XXXXXXXX, XXXXX. Diamyd Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).